Kyntra Bio stock falls 3.02 percent as board changes

Published on 10/05/2026 at 20:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kyntra Bio stock carries a board catalyst from October 1, 2026, when Andrew E. Singer joined its Audit Committee. Q2 revenue was USD -1.5 million against a USD 2.09 million forecast.

KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio stock (ISIN US31572Q8814) was trading at USD 6.12 on Nasdaq on October 5, 2026, down 3.02 percent from the previous close. The company appointed Andrew E. Singer as an independent director and Audit Committee member effective October 1, while Maykin Ho left the board effective September 30, according to GlobeNewswire on October 1, 2026.

Board change meets a weak tape

Singer brings more than 25 years of experience in biotechnology finance, corporate strategy, business development and public-company leadership, the company said in the October 1 release. His appointment gives Kyntra Bio an additional finance and strategy profile as the company advances programs in oncology and rare disease.

The market reaction remains measurable: KYNB opened at USD 6.36 and traded between USD 5.83 and USD 6.45 during the October 5 session. Its market capitalization stood at USD 24.8 million, while volume reached 80,061 shares at the quoted time.

Q2 figures sharpen the risk profile

The latest Q2 2026 earnings entry dated August 13 lists revenue of USD -1.5 million and diluted EPS of USD 2.96, against a revenue forecast of USD 2.09 million and an EPS forecast of USD -3.18, according to Investing.com.

That comparison puts the board news in context: the valuation is small, but the operating figures remain volatile. Kyntra Bio is developing FG-3246, a Phase 2 antibody-drug conjugate targeting CD46, and is evaluating a Phase 3 roxadustat program for lower-risk myelodysplastic syndromes, according to the company release.

Consensus target stays far higher

Investing.com lists four analysts, with three Buy ratings and one Hold rating, producing a Strong Buy consensus. The average 12-month target is USD 39.667, with a low of USD 35.00 and a high of USD 43.00; the average target lies 548.15 percent above the USD 6.12 price.

The next scheduled earnings date is November 9, 2026, according to Investing.com. For investors, the central tension is clear: the analyst valuation gap is large, while current revenue and the October 5 trading range point to a highly speculative biotechnology profile.

Kyntra Bio stock trades near its yearly low

KYNB was trading at USD 6.12 on Nasdaq on October 5, 2026, within a 52-week range of USD 5.62 to USD 12.13. The price was 8.90 percent above the 52-week low, leaving the board transition and November earnings date as the next concrete checkpoints.